CMS Names the Next 15 Meds Due for ‘Negotiation’

And HHS is working to identify and limit legal risks around TrumpRx and other pharm-to-table programs

Jan 28, 2026

Subscribe to Cost Curve Apex to read the rest.

Upgrade to Apex to get access to this post and other subscriber-only content.

No posts found